Ticagrelor Tablet
Product Images NDC 55488-0543

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 55488-0543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Changzhou Pharmaceutical Factory, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60mg-500ct (60mg 500ct)

Ticagrelor 60 mg oral tablets label showing 500 tablets per package. Manufactured by Changzhou Pharmaceutical Factory, Jiangsu, China, and distributed by Bionpharma Inc., Princeton, NJ. Label includes storage instructions, a warning to keep out of reach of children, and dosage note to see package insert. NDC 69452-508-30 is displayed along with a barcode.*

FDA Label Image

60mg-60ct (60mg 60ct)

Ticagrelor 60 mg tablets packaging label showing the active ingredient strength, quantity of 60 tablets, and manufacturer Changzhou Pharmaceutical Factory. The label includes storage instructions, warnings, distributor information (Bionpharma Inc.), and indicates the prescription-only status.*

FDA Label Image

90mg-500ct (90mg 500ct)

Label for Ticagrelor 90 mg tablets. The label shows the product name, strength, and form, manufactured by Changzhou Pharmaceutical Factory and distributed by Bionpharma Inc. It specifies a package size of 500 tablets, Rx only, with storage instructions and a barcode included.*

FDA Label Image

90mg-60ct (90mg 60ct)

Ticagrelor Tablets 90 mg oral tablets label showing active ingredient strength, quantity of 60 tablets, and manufacturer information. Produced by Changzhou Pharmaceutical Factory, distributed by Bionpharma Inc. Label includes storage instructions, warning to keep out of reach of children, and a barcode.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure diagram of ticagrelor, showing its molecular framework including hydroxyl groups, fluorophenyl rings, and a thiazole ring.*

FDA Label Image

Figure-01 (Figure 01)

A cumulative percentage curve graph comparing Ticagrelor 90 mg and Clopidogrel over 360 days from first study drug dose, showing event rates over time with Ticagrelor having slightly higher cumulative percentages. The graph includes numbers at risk for both drugs at several time points and a legend indicating patient counts and percentages with events.*

FDA Label Image

Figure-02 (Figure 02)

A bar chart showing the percentage of patients experiencing an event following CABG surgery over a series of days. The x-axis represents days post-surgery (1 through ≥8), and the y-axis shows the percentage of patients. Two groups are compared, labeled T and C, with data points and counts included below the x-axis. The chart compares event rates over time between these two groups.*

FDA Label Image

Figure-03 (Figure 03)

A Kaplan-Meier cumulative percentage graph displaying events over months from randomization comparing Ticagrelor (solid line) and Placebo (dashed line). The x-axis shows time in months up to 54, and the y-axis shows cumulative percentage events. Ticagrelor has higher cumulative events than Placebo. Below the graph, patient counts at risk for each group are listed at various time points.*

FDA Label Image

Figure-04 (Figure 04)

A cumulative percentage line graph comparing Ticagrelor 90 mg twice daily to placebo over approximately 30 days following randomization. The solid line represents Ticagrelor with higher cumulative percentages, and the dashed line represents placebo with lower cumulative percentages. A table below shows the number of patients at risk for each group at various time points.*

FDA Label Image

Figure-05 (Figure 05)

A line graph comparing the inhibitory platelet aggregation (IPA %) induced by 20 µM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. The Ticagrelor line shows a rapid increase in IPA reaching near 90%, Clopidogrel rises more gradually to about 50%, while placebo remains low, below 15%, across 8 hours.*

FDA Label Image

Figure-06 (Figure 06)

A line chart showing IPA (%) induced by 20uM ADP over a 10-day period, with three data series represented by circles, triangles, and squares. An inset graph depicts IPA (%) induced by 20uM ADP over 48 hours with similar data points and markers. The x-axes represent time in days (main chart) and hours (inset), while the y-axes represent IPA percentage values.*

FDA Label Image

Figure-07 (Figure 07)

A pharmacokinetic chart showing the mean effect and 90% confidence interval for Ticagrelor and a comparator labeled AR-C124910XX across various intrinsic factors including age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The chart presents changes relative to reference for parameters Cmax and AUC, with a recommendation of no dose adjustment across all factors.*

FDA Label Image

Figure-08 (Figure 08)

A graph showing the mean effect and 90% confidence interval of various interacting drugs on Ticagrelor and AR-C124910XX. The x-axis represents change relative to reference with values from 0 to 8. Interacting drugs like Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl are listed with corresponding pharmacokinetic parameters Cmax and AUC indicated by squares and triangles. Recommendations include dose adjustments or avoidance for some drugs, with references to specific sections for Morphine and Fentanyl.*

FDA Label Image

Figure-09 (Figure 09)

A pharmacokinetic chart showing the mean effect and 90% confidence interval of ticagrelor drug interactions with various drugs (Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, Cyclosporine). The horizontal axis represents change relative to interacting drug alone, with markers for Cmax and AUC effects. Recommendations on dose adjustments are listed, including a maximum simvastatin dose of 40 mg and monitoring digoxin levels with ticagrelor therapy changes.*

FDA Label Image

Figure-10 (Figure 10)

A line graph comparing the cumulative percentage of patients with events over 360 days from randomization between Ticagrelor 90 mg and Clopidogrel. The graph shows Ticagrelor with a lower cumulative event percentage than Clopidogrel throughout the period, with additional risk and statistical information in an inset box and patient counts at risk over time listed below the x-axis.*

FDA Label Image

Figure-11 (Figure 11)

A forest plot comparing the hazard ratios (HR) and 95% confidence intervals (CI) for various characteristics between Ticagrelor and Clopidogrel treatment groups. The plot includes overall treatment effect, geographic region, ASA dose, treatment approach, patient subgroups, age, sex, and race, showing HR values along a horizontal axis indicating whether Ticagrelor or Clopidogrel is favored.*

FDA Label Image

Figure-12 (Figure 12)

A forest plot graph comparing hazard ratios (HR) with 95% confidence intervals for ticagrelor versus clopidogrel treatment outcomes in US and Non-US regions, stratified by aspirin (ASA) dose categories. The plot visualizes ticagrelor's relative efficacy or risk compared to clopidogrel based on different ASA dose ranges.*

FDA Label Image

Figure-13 (Figure 13)

A cumulative percentage line graph depicting event rates over approximately 3.5 years (days from randomization) for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The chart includes patient counts at risk over time for each group and a legend with hazard ratios, confidence intervals, and p-values comparing treatment effects.*

FDA Label Image

Figure-14 (Figure 14)

A forest plot chart depicting the treatment effect of Ticagrelor versus placebo across various patient subgroups. The plot shows hazard ratios (HR) with 95% confidence intervals for overall treatment effect and subcategories like age group, sex, race, weight, BMI, geographic region, medical history, and other clinical variables. Each subgroup displays comparison data for Ticagrelor and placebo groups, indicating relative efficacy outcomes.*

FDA Label Image

Figure-15 (Figure 15)

A line graph comparing cumulative percentage over months from randomization between Ticagrelor and placebo groups. The x-axis represents months from 0 to 54 and the y-axis shows cumulative percentage from 0% to 14%. Solid and dashed lines respectively represent Ticagrelor and placebo. A table below lists the number of patients at risk for each group over time.*

FDA Label Image

Figure-16 (Figure 16)

A forest plot comparing the hazard ratio (HR) with 95% confidence intervals (CI) of Ticagrelor versus placebo across various patient characteristics including age, sex, race, body mass index, geographic region, aspirin dose, HbA1c, eGFR, insulin use, history of angina, coronary artery disease, PCI, stent, CABG, smoking, and diabetes duration. The plot displays subgroup-specific HRs illustrating relative efficacy outcomes in different patient populations.*

FDA Label Image

Figure-17 (Figure 17)

A cumulative percentage line graph comparing events over days from randomization for Ticagrelor 90 mg twice daily versus placebo. The x-axis represents days from randomization (0 to 34), and the y-axis shows cumulative percentage (0 to 8%). Two lines display event rates: a solid line for Ticagrelor and a dashed line for placebo, with numeric event counts and risk population sizes noted below the graph.*

FDA Label Image

Figure-18 (Figure 18)

A forest plot chart showing hazard ratios (HR) with 95% confidence intervals comparing Ticagrelor versus placebo across various patient subgroups including age, sex, race, weight, BMI, geographic region, stroke diagnosis, time from event to randomization and loading dose, diabetes, hypertension, prior ischemic events, statin treatment, and smoking status. The plot visualizes the relative effectiveness of Ticagrelor against placebo in each subgroup with HR values and percentages listed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.